Bortemib 2 mg Injection
In stock
Description
Bortezomib 2 mg/mL is a specialized antineoplastic injection utilized as a potent proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma. It is frequently administered subcutaneously (2.5 mg/mL) or intravenously (1 mg/mL) and works by disrupting normal cell protein degradation, leading to apoptosis of cancer cells.
Specifications
| Strength | 2 mg/vial |
|---|---|
| Route of Administration | Intravenous (IV) |
| Therapeutic Class: | Proteasome Inhibitor |
| Formulation | Lyophilized powder for injection (or sometimes liquid) |
| Main Ingredients | Bortezomib Injection IP 2 mg |
| Uses | Multiple Myeloma, Mantle Cell Lymphoma |
